Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Increased by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 3.2% during the third quarter, Holdings Channel reports. The firm owned 936,197 shares of the company’s stock after buying an additional 29,017 shares during the period. Geode Capital Management LLC’s holdings in Mirum Pharmaceuticals were worth $36,519,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in MIRM. State Street Corp increased its position in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares during the period. Rice Hall James & Associates LLC boosted its stake in Mirum Pharmaceuticals by 6.9% during the 2nd quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock valued at $7,854,000 after purchasing an additional 14,843 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at $17,384,000. Charles Schwab Investment Management Inc. raised its stake in shares of Mirum Pharmaceuticals by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after buying an additional 17,149 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Mirum Pharmaceuticals by 48.2% in the second quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock valued at $4,889,000 after buying an additional 46,506 shares during the period.

Mirum Pharmaceuticals Stock Up 1.1 %

NASDAQ:MIRM opened at $42.17 on Thursday. The business’s fifty day moving average price is $42.32 and its 200 day moving average price is $39.68. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -20.88 and a beta of 1.20. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm’s quarterly revenue was up 89.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.57) EPS. On average, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the sale, the senior vice president now owns 2,426 shares of the company’s stock, valued at $114,264.60. This trade represents a 50.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 22.87% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. HC Wainwright restated a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Citigroup increased their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.